Insomnia News and Research RSS Feed - Insomnia News and Research

Insomnia is too little or poor-quality sleep caused by one or more of the following:

Trouble falling asleep
Waking up a lot during the night with trouble returning to sleep
Waking up too early in the morning
Having un-refreshing sleep (not feeling well rested), even after sleeping 7 to 8 hours at night

Insomnia can cause problems during the day, such as excessive sleepiness, fatigue, trouble thinking clearly or staying focused, or feeling depressed or irritable. It is not defined by the number of hours you sleep every night. Although the amount of sleep a person needs varies, most people need between 7 and 8 hours of sleep a night.
Roseroot extract may be beneficial for treating major depressive disorder

Roseroot extract may be beneficial for treating major depressive disorder

Rhodiola rosea (R. rosea), or roseroot, may be a beneficial treatment option for major depressive disorder (MDD), according to results of a study in the journal Phytomedicine led by Jun J. Mao, MD, MSCE, associate professor of Family Medicine, Community Health and Epidemiology and colleagues at the Perelman School of Medicine of University of Pennsylvania. [More]
Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced its plans for the commercialization of SPRIX (ketorolac tromethamine) Nasal Spray and OXAYDO (oxycodone HCI, USP) tablets for oral use only –CII. [More]
Egalet announces net revenues of $1.9 million for 2014

Egalet announces net revenues of $1.9 million for 2014

Egalet Corporation today reported financial results for the year ended December 31, 2014. [More]
AASM publishes new quality measures for common sleep disorders

AASM publishes new quality measures for common sleep disorders

Today the American Academy of Sleep Medicine published new quality measures for five common sleep disorders, which represents a landmark achievement in the promotion of high quality, patient-centered care in the medical subspecialty of sleep medicine. [More]
Insomnia symptoms affect suicide risk among people who drink alcohol

Insomnia symptoms affect suicide risk among people who drink alcohol

Insomnia symptoms affect the risk of suicide among people who drink alcohol, according to a groundbreaking study led by the director of Mississippi State University's Sleep, Suicide and Aging Laboratory. [More]
Depression symptoms under-recognized in African-American cancer patients

Depression symptoms under-recognized in African-American cancer patients

Case Western Reserve University nurse scientist Amy Zhang, who has long examined quality-of-life issues in cancer patients, wondered whether depression in African-American cancer patients has been under-recognized for treatment. [More]
AAPMD announces "The Silent Airway Problem: Connecting the Dots" conference

AAPMD announces "The Silent Airway Problem: Connecting the Dots" conference

The American Academy of Physiological Medicine and Dentistry (AAPMD) is leading the charge for an interdisciplinary medical approach to the diagnosis and treatment of sleep and breathing disorders, which research indicates contribute to a range of serious physiological, cognitive, behavioral and performance conditions in children and adults. [More]
Anticholinergic medications associated with pneumonia risk in older people

Anticholinergic medications associated with pneumonia risk in older people

Taking commonly used medications with anticholinergic effects is associated with a significantly higher risk for developing pneumonia in a study of more than 3,000 older Group Health patients living in the community--not in nursing homes. [More]
Study: Persistent insomnia increases mortality risk

Study: Persistent insomnia increases mortality risk

A connection between persistent insomnia and increased inflammation and mortality has been identified by a group of researchers from the University of Arizona. Their study, published in The American Journal of Medicine, found that people who suffer from persistent insomnia are at greater risk than those who experience intermittent insomnia. [More]
Researchers warn doctors, parents not to give melatonin drug to control sleep problems in children

Researchers warn doctors, parents not to give melatonin drug to control sleep problems in children

Sleep researchers at the University of Adelaide are warning doctors and parents not to provide the drug melatonin to children to help control their sleep problems. [More]
New study could lead to better remedies for insomnia, more effective anaesthetic drugs

New study could lead to better remedies for insomnia, more effective anaesthetic drugs

Scientists have discovered that switching on one area of the brain chemically can trigger a deep sleep. [More]
International study shows potential new therapy to treat patients with neuropathic pain

International study shows potential new therapy to treat patients with neuropathic pain

An international study led by scientists at McGill University reports, for the first time, that drugs that selectively target the melatonin MT2 receptor represent a novel class of analgesic drugs that could be used to treat patients with neuropathic pain. [More]
Rutgers patient gets second chance at life following liver transplant

Rutgers patient gets second chance at life following liver transplant

Mati Muñoz is 65 years old - filled with the enthusiastic energy that comes with a second chance at life. A decade ago, says Muñoz, who lives in Woodbridge Township, N.J., her liver was being destroyed by hepatitis C, a viral disease she believes she contracted as a girl in her native Cuba from a poorly sterilized needle used in a medical procedure. [More]
Merck announces US availability of BELSOMRA (suvorexant) for treatment of insomnia

Merck announces US availability of BELSOMRA (suvorexant) for treatment of insomnia

Merck, known as MSD outside the United States and Canada, today announced that BELSOMRA (suvorexant) is now available at pharmacies in the United States for the treatment of insomnia in adults who have difficulty falling asleep and/or staying asleep. [More]
Insomnia treatment in veterans linked to significant reduction in suicidal ideation

Insomnia treatment in veterans linked to significant reduction in suicidal ideation

A new study is the first to show that the treatment of insomnia in veterans is associated with a significant reduction in suicidal ideation. [More]
Shire announces FDA approval of Vyvanse Capsules for binge eating disorder

Shire announces FDA approval of Vyvanse Capsules for binge eating disorder

Shire plc announced today that the U.S. Food and Drug Administration approved Vyvanse (lisdexamfetamine dimesylate) Capsules (CII), the first and only medication for the treatment of moderate to severe binge eating disorder (B.E.D.) in adults, shown to significantly reduce the mean number of binge days per week. [More]
Menopause does not exacerbate or cause sleep problems, shows study

Menopause does not exacerbate or cause sleep problems, shows study

Women in their late thirties and forties who have trouble sleeping are more than three times more likely to suffer sleep problems during menopause than women who have an easier time getting shut-eye, according to a new study by researchers from the Perelman School of Medicine at the University of Pennsylvania. [More]
FDA approves RYTARY for Parkinson's disease treatment

FDA approves RYTARY for Parkinson's disease treatment

Impax Pharmaceuticals, a division of Impax Laboratories, Inc., today announced that the U.S. Food and Drug Administration approved RYTARY, an extended-release oral capsule formulation of carbidopa-levodopa, for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication and / or manganese intoxication. [More]
FDA approves Hospira's Dyloject (diclofenac sodium) Injection for pain management

FDA approves Hospira's Dyloject (diclofenac sodium) Injection for pain management

Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, has received approval from the U.S. Food and Drug Administration for Dyloject (diclofenac sodium) Injection, a proprietary nonsteroidal anti-inflammatory drug (NSAID) analgesic. [More]
First successful vaccination of deer against chronic wasting disease

First successful vaccination of deer against chronic wasting disease

Researchers at NYU Langone Medical Center and elsewhere say that a vaccination they have developed to fight a brain-based, wasting syndrome among deer and other animals may hold promise on two additional fronts: Protecting U.S. livestock from contracting the disease, and preventing similar brain infections in humans. [More]
Advertisement
Advertisement